Search

Learn more about the new FDA-approved drug repotrectinib (AugtyroTM), which targets ROS1 fusions in lung cancer and other cancer types.

… Wednesday, January 10, 2024 Ingrid Adams, now 68, has been coping with metastatic lung cancer for more than a decade. Standard treatment — including chemotherapy and radiation therapy — kept her disease under control for a while, but the cancer continued to spread. Everything changed when she came to

Obtenga más información sobre el nuevo fármaco aprobado por la FDA, repotrectinib (AugtyroTM), que ataca las fusiones de ROS1 en el cáncer pulmonar y otros tipos de cáncer.

… Wednesday, January 10, 2024 Ingrid Adams, que ahora tiene 68 años, ha estado lidiando con el cáncer pulmonar metastásico durante más de una década. El tratamiento estándar, que incluye quimioterapia y radioterapia , mantuvo su enfermedad bajo control por un tiempo, pero el cáncer continuó diseminándose

Learn what can be done for patients like Stephanie Soto-Vega who confront financial hardships caused by cancer.

… Thursday, April 10, 2025 It was hard enough for Stephanie Soto-Vega to get the news that her breast cancer had spread to her hip bones and spine. Then came another blow: Her insurance company wouldn’t cover the medication to keep the cancer under control. It cost $15,000 a month. “I was really worried

Meet a few of our brave and determined young patients who are thriving after receiving treatment at MSK.

… Friday, October 1, 2021 Ending cancer treatment is an exciting yet tricky transition for adolescents and young adults. But MSK keeps a close eye on these survivors as their physical, emotional, and social needs change over time. There are three survivorship clinics — each tailored to a specific age group

Learn more about the first facility in the world devoted to the specific needs of colorectal cancer patients under the age of 50.

… Monday, March 8, 2021 Summary A troubling rise in colorectal cancer among younger adults has led experts to advise issuing new guidelines that lower the recommended age when people should begin colorectal screenings from 50 to 45. In 2018, MSK established the first facility in the world devoted to the

Obtenga más información sobre el primer centro en el mundo dedicado a las necesidades específicas de los pacientes con cáncer colorrectal menores de 50 años.

… Monday, March 8, 2021 Resumen Un aumento preocupante de casos de cáncer colorrectal entre los adultos más jóvenes ha llevado a los expertos a sugerir que se publiquen nuevas pautas que reduzcan la edad recomendada en que las personas deben comenzar a hacerse las pruebas de detección colorrectal de los

Discover where three recent Gerstner Sloan Kettering graduates are now and learn about the research they’re pursuing.

… Tuesday, September 20, 2016 Gerstner Sloan Kettering graduate James Mahaffey works in a lab at the Perlmutter Cancer Center at NYU School of Medicine exploring the RAS gene, which is mutated in nearly a third of cancers but has resisted targeting with drugs. James Mahaffey studies RAS, a gene that is

Memorial Sloan Kettering’s suburban presence is expanding with its newest and largest state-of-the-art facility set to welcome patients on October 6 in West Harrison, New York.

… Wednesday, October 1, 2014 VIDEO | 04:30 Virtual Tour of Memorial Sloan Kettering Cancer Center Westchester Take a virtual tour of our suburban outpatient location and hear from our doctors on the benefits of receiving care at MSK Westchester. Video Details Memorial Sloan Kettering’s suburban presence

Experiments with zebrafish and human pluripotent stem cells reveal the necessary ingredients, besides genetic mutations, that fuel the development of melanoma.

… Friday, September 3, 2021 Right now, in your body, lurk thousands of cells with DNA mistakes that could cause cancer. Yet only in rare instances do these DNA mistakes, called genetic mutations, lead to a full-blown cancer. Why? The standard explanation is that it takes a certain number of genetic “hits

… Tuesday, December 2, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Omar Abdel-Wahab Elected to the National Academy of Medicine (NAM) Omar Abdel-Wahab Omar Abdel-Wahab, MD , Chair of the Molecular Pharmacology Program at Sloan Kettering Institute